Synta Pharmaceuticals (SNTA +2.8%) gains after saying a study of ganetespib, its lead drug candidate, showed positive results as a treatment for oncologic indications, including a reduced rate of ocular toxicity. SNTA's primary research focus is on treatments for severe conditions such as cancer and chronic inflammatory diseases.
Synta Pharmaceuticals (SNTA +2.8%) gains after saying a study of ganetespib, its lead drug...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs